Form 4: Amphastar Pharmaceuticals Director Floyd F. Petersen Reports Stock Sale and Option Grant

Director Floyd F. Petersen of Amphastar Pharmaceuticals reports the sale of 500 shares and acquisition of 3,076 restricted stock units, along with an option to purchase 6,864 shares.

Summary

• On June 3, 2024, Floyd F. Petersen, a director at Amphastar Pharmaceuticals, sold 500 shares of common stock at a weighted average price of $42.6518.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2023.
• Petersen also acquired 3,076 restricted stock units (RSUs) and an option to buy 6,864 shares of common stock, both vesting on June 3, 2025.
• Following these transactions, Petersen directly owns 78,333 shares of common stock and holds options for 6,864 shares.
• The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 3, 2025.
• All of the shares subject to the option vest on June 3, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The sale of shares is offset by the acquisition of RSUs and stock options, suggesting continued confidence in the company's future. The pre-arranged trading plan mitigates concerns about opportunistic selling.

Positives

• The acquisition of RSUs and stock options indicates a continued alignment of the director's interests with the company's long-term performance.

Negatives

• The sale of 500 shares, while part of a pre-arranged plan, could be interpreted negatively by some investors.

Risks

• The market's reaction to insider sales, even if pre-planned, can be unpredictable.
• The vesting of RSUs and stock options is contingent on continued service, which introduces a dependency on Petersen's ongoing involvement with the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge sentiment and potential future actions by key personnel.

Comparison to Industry Standards

• Insider trading activities are common across publicly listed companies, and the reporting requirements are standardized by the SEC.
• The use of Rule 10b5-1 trading plans is a common practice to allow insiders to sell shares without being accused of trading on non-public information, similar to practices at companies like Teva Pharmaceuticals and Mylan (now Viatris).

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how the market interprets the insider activity.
• The vesting of RSUs and stock options could incentivize the director to continue contributing to the company's success.

Key Dates